These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 38112859)
1. Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients. An Y; Lu W; Li S; Lu X; Zhang Y; Han D; Su D; Jia J; Yuan J; Zhao B; Tu M; Li X; Wang X; Fang N; Ji S Discov Oncol; 2023 Dec; 14(1):234. PubMed ID: 38112859 [TBL] [Abstract][Full Text] [Related]
2. Identification of microRNA signature and potential pathway targets in prostate cancer. Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835 [TBL] [Abstract][Full Text] [Related]
3. Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer. Zhang Y; Mou Y; Liang C; Zhu S; Liu S; Shao P; Li J; Wang Z Prostate; 2021 Feb; 81(3):157-169. PubMed ID: 33338276 [TBL] [Abstract][Full Text] [Related]
4. Systematic Review of Prognostic Gene Signature in Gastric Cancer Patients. Xie L; Cai L; Wang F; Zhang L; Wang Q; Guo X Front Bioeng Biotechnol; 2020; 8():805. PubMed ID: 32850704 [TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981 [TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866 [TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients. Zhang R; Liu F J Transl Med; 2022 Oct; 20(1):453. PubMed ID: 36195908 [TBL] [Abstract][Full Text] [Related]
9. A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients. Lan Y; Jia Q; Feng M; Zhao P; Zhu M Front Genet; 2023; 14():1100020. PubMed ID: 37035749 [No Abstract] [Full Text] [Related]
11. Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. Lai YL; Liu CH; Wang SC; Huang SP; Cho YC; Bao BY; Su CC; Yeh HC; Lee CH; Teng PC; Chuu CP; Chen DN; Li CY; Cheng WC Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326723 [TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Li R; Shui L; Jia J; Wu C Front Genet; 2020; 11():906. PubMed ID: 32922438 [TBL] [Abstract][Full Text] [Related]
13. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression. Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551 [TBL] [Abstract][Full Text] [Related]
14. Gene signature for prognosis in comparison of pancreatic cancer patients with diabetes and non-diabetes. Yang M; Song B; Liu J; Bing Z; Wang Y; Yu L PeerJ; 2020; 8():e10297. PubMed ID: 33240632 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts. Li R; Zhu J; Zhong WD; Jia Z Cancer Res; 2022 May; 82(9):1832-1843. PubMed ID: 35358302 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy. Cai Y; Lin J; Wang Z; Ma Y; Pan J; Liu Y; Zhao Z Front Oncol; 2022; 12():1009921. PubMed ID: 36324578 [TBL] [Abstract][Full Text] [Related]
17. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer. Hou X; Zhang Y; Han S; Hou B Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649 [TBL] [Abstract][Full Text] [Related]
18. Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer. Xu L; Pan J; Ding Y; Pan H Front Genet; 2020; 11():522383. PubMed ID: 33193606 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer. Liu X; Wang K Front Genet; 2023; 14():1166668. PubMed ID: 37719710 [No Abstract] [Full Text] [Related]
20. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer. Cava C; Bertoli G; Colaprico A; Bontempi G; Mauri G; Castiglioni I Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]